BWX Technologies: Record $8.7 Billion Backlog and a Deliberate Push Into U.S. Commercial Nuclear Manufacturing Signal a Structural Step-Change
Q1 2026 Earnings Call, May 4, 2026 — BWXT beats on all key metrics and lays out an ambitious domestic capacity build
BWX Technologies opened 2026 with one of its strongest quarterly performances in recent memory, but the more consequential story out of Monday's earnings call was not the numbers themselves — it was management's increasingly concrete articulation of a plan to establish a U.S. commercial nuclear manufacturing footprint, a strategic move that could materially reshape the company's long-term revenue mix and competitive positioning in what CEO Rex Geveden described as a market heading toward "hundreds and hundreds of reactors globally."
Financials Beat Across the Board, Guidance Raised
First quarter revenue came in at $860 million, up 26% year-over-year with 11% organic growth. Adjusted EBITDA grew 14% to $148 million, and adjusted earnings per share rose 22% to $1.12, all ahead of internal and external expectations. Commercial Operations was the standout, with revenue up 121% in total and 39% organically, driven by accelerated throughput on large component projects — notably the Pickering life extension steam generators — and another strong quarter from the Kinectrics acquisition. Government Operations grew a steadier 4% in revenue with EBITDA margins of 20.4%, slightly better than plan.
Free cash flow of $50 million in what is seasonally the company's weakest quarter was described by CFO Mike Fitzgerald as a strong result, reflecting solid earnings and disciplined working capital management. Full-year guidance was nudged upward: revenue of at least $3.75 billion (high-teens growth), adjusted EBITDA of $650 million to $665 million (up $5 million on each end), and non-GAAP EPS of $4.60 to $4.75. Free cash flow guidance of $315 million to $330 million was maintained. Importantly, none of these figures include any contribution from the recently announced acquisition of Precision Components Group, which is expected to close in the second half of the year.
The PCG Acquisition: A $200 Million First Step Toward U.S. Commercial Scale
The acquisition of Precision Components Group — confirmed on the call to carry a price tag of roughly $200 million — is the most tangible near-term expression of BWXT's commercial manufacturing ambitions. PCG operates two facilities in New York/Pennsylvania and Florence, New Jersey, employs more than 400 nuclear-qualified workers, and generated approximately $125 million of revenue with low double-digit EBITDA margins in 2025. Mid-single digit revenue growth is anticipated for 2026.
Critically, PCG's current revenue is weighted roughly 70% naval and government, 30% commercial nuclear. Management was direct about the intent to shift that mix. "One of the things that we can do right away is we can move some work that we've been outsourcing from our commercial business right into those plants," Geveden said. "In so doing, we can capture the profits that are otherwise going to the supply chain." Fitzgerald added that PCG currently has approximately 50% available capacity, though he cautioned that fully ramping that utilization — through hiring of perhaps a few workers per week — will take "a few years." The near-term margin accretion from in-sourcing is real but modest; the longer-term business case rests on a multi-year ramp.
A key structural advantage embedded in the acquisition that should not be overlooked: nuclear manufacturing credentials. As Geveden explained, "Nuclear manufacturing credentials are rare and hard to get. You have to go through certifications to get stamps — N stamps, NPT stamps, U stamps. These are ASME-certified factories that also have nuclear quality systems. And so that's hard to get, and it's an immediate capability for us."
Mount Vernon Greenfield: The Heavier Lift, Literally and Financially
PCG handles complex heat transfer components — reactor internals, pressurizers, heat exchangers, reactor head assemblies — but it cannot produce the largest, heaviest nuclear equipment. For that, BWXT is advancing plans for a greenfield facility at its existing Mount Vernon, Indiana site, which would be capable of manufacturing steam generators and reactor pressure vessels. Geveden sized the planned facility at roughly 100,000 square feet — approximately 50% to 60% larger than the 60,000 square foot brownfield expansion currently underway at the Cambridge, Ontario plant — and estimated the cost at "roughly twice what we're doing in Cambridge." Fitzgerald indicated that this greenfield investment, if approved, would push annual capital expenditure from the current 6%-of-sales guidance toward approximately 7%, but he was explicit that the company would not return to the 9% to 10% CapEx intensity of the prior decade.
The Mount Vernon site already has a rail spur, crane capacity rated to 1,000 metric tons, and radiography facilities — cost synergies that meaningfully reduce the effective greenfield premium. The timeline to operationality is two to three years from a final investment decision, which management views as appropriately aligned with the expected timing of large component orders from the wave of new reactor projects currently being negotiated. "We're trying to skate to where we think the puck is going," Geveden said, "because these are such long cycle projects and you have to have the capacity — the existential capacity — when the order comes."
On the question of whether customer funding might derisk this commercial capacity build, Geveden was notably self-reliant: "We have the balance sheet to do what we need to do."
Backlog at $8.7 Billion, Up 77% Year-Over-Year — The Demand Signal Is Real
Total company backlog ended the quarter at $8.7 billion, up 77% year-over-year and 19% sequentially. Government Operations backlog reached nearly $7 billion, up 93% year-over-year and 25% sequentially, boosted by a $1.4 billion booking from the second portion of the naval reactors pricing agreement and long-lead material procurement contracts. Commercial Operations backlog was flat sequentially but up 33% year-over-year following an 85% increase in 2025, supporting the low-teens organic commercial power growth expectation for the full year.
The breadth of demand signals management cited was notable. The U.S.-Japan announcement of up to $40 billion to build as many as ten GE Hitachi BWRX-300 SMRs in the southeastern United States was called out directly, as was a separate set of ten AP1000 large reactors under discussion. Geveden said he is "in touch with the top leadership of GE and Westinghouse" and that these deals "are being negotiated with urgency" through the Department of Commerce, adding that orders related to these bulk reactor buys arriving in 2026 "wouldn't surprise me." He was careful to note the hurdles remaining, but the directionality was unmistakable. BWXT's role as the reactor vessel supplier on the first BWRX-300 at Darlington, Ontario — with delivery of the first pressure vessel expected as early as next year — gives it a credible reference position for the U.S. program.
Government Operations: Steady Core, With Enrichment Programs Now Visibly Moving
The government segment delivered predictable, if unspectacular, performance. More important for long-term investors is the progress on the defense fuels enrichment and High-Purity Depleted Uranium (HPDU) programs, which together are expected to account for more than half of government segment revenue growth in 2026. Construction of the Centrifuge Manufacturing Development Facility in Oak Ridge was completed earlier this year, prototyping of the first centrifuge units has begun, and BWXT engaged with the NRC in April regarding plans for a High-Enriched Uranium enrichment facility in Erwin, Tennessee — a regulatory milestone that aligns the company with the NRC's approval process. The new large HPDU contract facility in Jonesborough, Tennessee is in supply chain organization and pre-construction phases.
On the naval side, Geveden flagged an emerging opportunity: the FY27 budget request includes long-lead procurement for additional Columbia-class submarines, and there are early signals of added Columbia units to the force structure. Combined with the AUKUS program, "our naval nuclear propulsion program looks more robust and more interesting than it did even a couple of years ago," he said. On Korean nuclear submarines, Geveden acknowledged sovereign intent from Seoul and suggested that fuel supply — potentially from BWXT — is a logical question, but characterized it as "very immature" and dependent on direction from the U.S. Naval Reactors program.
Commercial Operations: Kinectrics Continues to Outperform; Medical Remains a Growth Engine
Kinectrics, acquired in 2024, continues to exceed its acquisition business case. A headline win in the quarter was its selection as design and fabrication partner for a U.K. tritium loop facility — described as the world's largest and most advanced tritium fuel cycle facility — which constitutes an entry point into the nuclear fusion market for engineering services and specialty equipment. Kinectrics also has a growing high-voltage testing and grid infrastructure business, currently about 10% of its total revenue, with particularly strong momentum in portable cable testing for European offshore wind. When asked about data center exposure, Geveden acknowledged the probability of some direct exposure but declined to size it.
Medical continues to compound well, with high-teens growth guided for 2026 after three consecutive years of approximately 20% CAGR. Strontium, germanium, TheraSphere, and Actinium-225 are all growing, with ytterbium-176 production ramping as a newer stabilized isotope offering. Technetium-99 remains in development with no revenue in the 2026 forecast, as the company continues to evaluate its market approach.
TRISO Fuel: The Only Producer at Scale, With Bigger Plans
BWXT remains the only producer of TRISO fuel at any commercial scale, currently producing "hundreds of kilograms a year" — enough to fuel its own Pele microreactor and supply Antares and undisclosed other clients. Geveden was clear-eyed about the constraint: "That is sort of the limit of our capacity now." The path to relevance at commercial scale requires a much larger facility, and the company has spoken publicly about a potential large-scale TRISO plant in Wyoming. Geveden's "betting on the race, not the horse" framing was explicit: BWXT intends to be the fuel supplier across reactor platforms, not just for its own designs. The ramp in TRISO capacity, if executed, could become a meaningful and differentiated revenue stream as microreactor and SMR projects move from demonstration to commercial deployment.
Capital Allocation and the EPC Risk the Company Cannot Control
BWXT's capital allocation posture is deliberate but increasingly growth-oriented. Full-year 2026 CapEx guidance remains at approximately 6% of sales, with upward pressure possible if the Mount Vernon greenfield proceeds. Fitzgerald's 7% ceiling comment was a useful data point for modeling. The company has leverage capacity to fund the PCG acquisition and organic expansion simultaneously without returning to the high-CapEx regime of prior years.
The one genuinely candid moment of the call came when Geveden was pressed on engineering, procurement, and construction delivery risk for the broader nuclear resurgence. He acknowledged it directly: "I think the bigger risk is on the engineering procurement and construction side, and that's a problem that the Bechtels and the Fluors of the world are going to have to solve." He cited AI and robotic construction as potential partial solutions but was unequivocal that it is "not a thing BWXT can address" and represents "a gating item for the success of the nuclear resurgence." It is a rare and important acknowledgment from a nuclear equipment supplier that the macro opportunity is real but the delivery infrastructure surrounding it remains a material execution risk — one entirely outside BWXT's control.
BWX Technologies Deep Dive
The Architecture of a Nuclear Monopoly
BWX Technologies operates at the apex of the nuclear industrial complex, functioning as the quintessential picks-and-shovels provider for both national security and the commercial nuclear energy renaissance. The company monetizes its specialized expertise across two primary reporting segments: Government Operations and Commercial Operations. The government business serves as the foundational bedrock of the enterprise, generating the vast majority of consolidated revenue by designing and manufacturing highly engineered nuclear reactors, components, and specialized fuel for the United States Navy. This segment effectively powers the American nuclear maritime fleet, specifically providing the propulsion systems for the Virginia-class and Columbia-class submarines, as well as the Ford-class aircraft carriers. Beyond naval propulsion, this division monetizes technical expertise by operating highly complex, contractor-managed Department of Energy facilities and conducting environmental remediation of special nuclear materials. Conversely, the Commercial Operations segment acts as a high-growth vector designed to capture the structural tailwinds of decarbonization and advanced healthcare. The company monetizes this commercial arm through long-term service contracts for CANDU heavy-water reactors in Canada, heavy component manufacturing for next-generation small modular reactors, and the production of critical diagnostic and therapeutic radioisotopes. By balancing cost-plus and fixed-price incentive defense contracts with high-margin commercial and healthcare revenues, BWX Technologies has constructed an exceptionally durable cash-generative business model.
Customer Concentration and The Supply Chain Matrix
The customer topology of BWX Technologies is heavily skewed toward sovereign entities, creating a highly concentrated but exceptionally reliable revenue base with virtually zero counterparty credit risk. The United States government, primarily via the Naval Nuclear Propulsion Program, is the absolute apex customer, historically accounting for roughly 80% of aggregate revenues. The ultimate end customers for the government manufacturing segment are the prime shipyards that assemble the naval vessels, primarily General Dynamics Electric Boat and Huntington Ingalls Industries. These massive shipbuilders are fundamentally reliant on the reactor cores delivered by BWX Technologies, making the company an indispensable node in the defense supply chain. On the commercial side, key customers include utility operators like Ontario Power Generation and major pharmaceutical players such as Bayer and Fusion Pharmaceuticals. The competitive landscape is remarkably sparse due to the extreme regulatory and capital barriers inherent to handling special nuclear materials. For naval reactors, direct competition is entirely non-existent. In the commercial nuclear domain, the company faces legacy equipment manufacturers like Westinghouse and Framatome, though it often collaborates rather than competes directly on specialized component manufacturing. The medical isotope space presents a more fragmented competitive matrix, featuring established global players like Curium and Lantheus, as well as emerging entrants. However, the supply chain for advanced nuclear materials is characterized by deep partnerships rather than zero-sum competition, evidenced by the company's collaborative supply agreements with NorthStar Medical Radioisotopes for therapeutic isotopes.
Market Share and Structural Moats
The competitive advantage of BWX Technologies is defined by an absolute, insurmountable monopoly in its core defense business. The company maintains a 100% market share as the sole-source supplier of nuclear reactors and fuel for the United States Navy submarines and aircraft carriers. Over the past seven decades, the firm has delivered over 420 naval reactor cores, creating a structural moat built on classified intellectual property, specialized human capital, and highly unique infrastructure. Operating over four million square feet of high-precision manufacturing space certified to exacting Nuclear Regulatory Commission and ISO 9001 standards requires capital expenditures and top-secret security clearances that effectively bar any new entrant from competing for naval propulsion contracts. This monopoly position translates into a massive, highly visible backlog, which exited 2025 at approximately $7.3 billion and expanded further with over $1.4 billion in new naval awards in early 2026. In the commercial segment, the company commands a dominant position in the Canadian heavy-water reactor service market and is rapidly gaining share as the primary domestic manufacturer in the small modular reactor supply chain. Furthermore, the firm is targeting a massive share of the diagnostic imaging market, as Technetium-99m is utilized in over 40 million medical procedures annually. By securing its role as the premier manufacturer across these critical verticals, the company extracts immense pricing power and revenue durability that is virtually unmatched in the broader industrial sector.
The Dual-Engine Growth Thesis
The industry dynamics surrounding nuclear technology have undergone a seismic shift, transitioning from a state of post-Fukushima stagnation to a structural supercycle driven by geopolitical tensions and the voracious energy demands of artificial intelligence data centers. For BWX Technologies, the primary opportunity lies at the exact intersection of these two macroeconomic mega-trends. The United States Navy's strategic imperative to modernize and expand its submarine fleet to counter peer adversaries in the Indo-Pacific guarantees a steady cadence of high-margin defense contracts well into the next decade, further supported by long-term secular tailwinds from the AUKUS trilateral security pact. Simultaneously, the global push for always-on, zero-carbon baseload power has positioned small modular reactors as the definitive solution for next-generation grid infrastructure and hyperscaler energy procurement. However, the thesis is not without inherent threats. The broader naval shipbuilding industrial base is currently strained by severe labor shortages and dry-dock bottlenecks at end-platform assemblers like General Dynamics and Huntington Ingalls. While BWX Technologies consistently delivers its reactors on schedule, cascading delays in downstream submarine assembly could theoretically alter the cadence of future procurement. Additionally, the space nuclear propulsion market recently experienced a material setback. The Defense Advanced Research Projects Agency cancelled the Demonstration Rocket for Agile Cislunar Operations program in mid-2025, calculating that the precipitous decline in traditional chemical launch costs driven by commercial space entities had eroded the near-term return on investment for nuclear thermal space propulsion. Despite this isolated cancellation, the terrestrial nuclear thesis remains entirely intact and accelerating.
Catalysts in Innovation: Medicine, Space, and SMRs
To diversify beyond the inherent lumpiness of defense procurement, the company is commercializing several disruptive technologies that are successfully transitioning from research and development into meaningful revenue and profit drivers. In the nuclear medicine vertical, the company has developed a proprietary, patent-pending neutron capture process to produce Molybdenum-99 using natural molybdenum targets rather than highly enriched uranium. By irradiating these targets at commercial power reactors like Ontario Power Generation's Darlington facility, this process fundamentally mitigates radioactive waste and nuclear proliferation concerns. With a New Drug Application submitted to the Food and Drug Administration, the resulting Technetium-99m generators are poised to capture significant market share as a drop-in, highly reliable supply chain replacement in the diagnostic space. Simultaneously, the firm is scaling the production of Actinium-225, a highly sought-after alpha-emitting isotope used in targeted cancer therapies, securing vital supply agreements with major pharmaceutical developers. In the advanced reactor space, the company has successfully pivoted from the cancelled space propulsion program to terrestrial microreactors, executing Project Pele for the Department of Defense. Having successfully delivered the highly durable TRISO fuel to the Idaho National Laboratory in late 2025, the 1.5-megawatt transportable microreactor is on track for a landmark demonstration by 2028. Furthermore, the company is manufacturing the massive reactor pressure vessel for GE Hitachi's BWRX-300 small modular reactor at the Darlington site in Canada, marking the first commercial SMR deployment in the Western world. As well-capitalized new entrants like NuScale and TerraPower attempt to commercialize novel reactor designs, BWX Technologies is perfectly positioned to act as the agnostic, picks-and-shovels manufacturer of critical components, capturing the upside of the nuclear renaissance without assuming the immense binary risk of regulatory reactor design failures.
The Steward of the Reactor: Management Track Record
Under the leadership of Chief Executive Officer Rex Geveden since 2017, the management team has executed a highly disciplined and visionary transformation of the enterprise. A former National Aeronautics and Space Administration executive, Geveden has successfully leveraged the company's legacy nuclear engineering credentials to establish robust commercial and medical verticals, effectively shifting the equity narrative from a pure-play defense contractor to a diversified nuclear technology powerhouse. Capital allocation has been highly strategic and opportunistic, perfectly illustrated by the April 2026 acquisition of Precision Components Group. This strategic buyout rapidly expanded the company's domestic heavy-manufacturing capacity for commercial nuclear components, adding over 500,000 square feet of manufacturing space and bringing in 400 skilled workers in a tight labor market. Financial execution over the last few years has been exceptionally strong, culminating in a record fiscal 2025 that saw the aggregate backlog grow by an astounding 50%. This fundamental momentum carried directly into the first quarter of 2026, with the company delivering 26% year-over-year revenue growth and raising full-year adjusted earnings guidance to a midpoint of $4.67 per share. However, the track record is not entirely devoid of friction. The primary critique levied against management involves the strict control of operating margins during this hyper-growth phase. In the first quarter of 2026, adjusted EBITDA margins contracted to 17.2% from 19.0% in the prior-year period, largely driven by an aggressive mix shift as the slightly lower-margin commercial business surged by 121% year-over-year. Nevertheless, management's ability to drive massive top-line expansion and swing free cash flow dramatically into positive territory demonstrates a high degree of operational competence and long-term strategic clarity.
The Scorecard
The investment narrative for BWX Technologies is anchored by an impenetrable monopoly in naval nuclear propulsion, granting the company a structural advantage that is virtually impossible to replicate in the modern industrial landscape. The absolute sole-source supplier status for the United States Navy provides a baseline of cash flow durability that highly insulates the balance sheet from broader macroeconomic volatility and cyclical industrial downturns. With a multi-year backlog comfortably exceeding $7 billion and the naval modernization supercycle structurally intact, the defense operations offer a supreme degree of revenue visibility. While localized supply chain bottlenecks at downstream shipbuilders require ongoing monitoring, the company's flawless execution on highly classified, critical-path reactor components solidifies its position as an indispensable, irreplaceable asset to the national security architecture of the United States.
Beyond the formidable defense moat, the company presents asymmetric fundamental upside through its strategic positioning in the commercial nuclear and radiopharmaceutical markets. The disciplined transition from a pure defense contractor to an agnostic manufacturer of small modular reactors and high-purity medical isotopes provides a potent secondary growth engine. Although the rapid scaling of these nascent commercial ventures has introduced temporary margin compression due to evolving revenue mix shifts, the long-term margin profile of targeted alpha therapies and global reactor components is highly compelling. The combination of a monopolistic, highly visible defense floor and the immense structural optionality tied directly to the global nuclear energy renaissance creates a robust industrial asset capable of compounding capital efficiently across multiple decades.